Hepa Wash Ranks 4th Place in Eurecan European Venture Contest Final

Munich, December21st, 2010 – Hepa Wash GmbH has ranked 4th place in the category “life sciences” in this years’ Eurecan European Venture Contest (EEVC) finale which took place on December 16th in Barcelona, Spain. The company competed with approximately 300 international companies in this category. In total nearly 1.000 companies from 24 countries participated in the three categories life sciences, information and communication technologies and clean tech. The EEVC is the largest competition of this kind worldwide.

The business concepts were reviewed by over 120 European experts representing funds such as Earlybird Venture Capital, Philips Healthcare Incubator and Veraventure Oy. The Final Jury was chaired by Mrs Diana Saraceni of 360° Capital Partners and involved some of Europe’s most active venture capital funds. “The innovation and investment potential of the finalists was truly outstanding”, Diana Saraceni said.

“We are very proud to have been chosen as one of the eight finalists in our category,” says Dr. Bernhard Kreymann, CEO of Hepa Wash GmbH. “The ranking shows that the efforts and successes our whole team made in the development of the Hepa Wash liver dialysis in the last five years are being honoured. In addition our concepts for the next three years concerning the build-up of production, performing the pivotal clinical study and market introduction have been judged as well planned and obviously the jury considers our future to be very promising”.

About Hepa Wash GmbH

Hepa Wash GmbH, which is located in the "Munich Technology Center" (MTZ), works since its foundation in 2005 on a new liver support therapy, to reduce the high mortality of critically ill patients with liver failure. Recent studies revealed that existing therapies can hardly achieve any positive effects on survival of liver patients. However, the Hepa Wash procedure has a significantly increased detoxication capacity and is therefore expected to improve the survival rate of affected patients for at least 30 percent. Two in-vitro- and preclinical studies already showed the imposing beneficial effects of the procedure. The clinical study at II. Medical Clinic in Hospital rechts der Isar started in September 2010. For this study a TUEV approved prototype of the device is used. In parallel to the pilot study the company finishes the device for the CE certification.

About Europe Unlimited Europe Unlimited delivers investment forums for young, high tech companies across Europe. Together with its online community of investors and entrepreneurs at www.e-unlimited.com, Europe Unlimited has delivered investment forums this year including the Nordic Venture Forum, Benelux Venture Forum, Cleantech Invest 2010, European Investment Summit and Tech Media Invest, 2010.

More Information Description of Hepa Wash technology.

Contact Daniela Becker, Press Officer

Hepa Wash GmbH Agnes-Pockels-Bogen 1 • 80992 Munich • Germany Phone: +49 (89) 4111842-24 • Fax: +49 (89) 4111842-09 Email: Daniela.Becker@hepawash.com • Web: www.hepawash.com CEO: PD Dr. Bernhard Kreymann • Chairman of the supervisory board: Harald Pinger Commercial register of the local court (Amtsgericht) München HRB 150 905 • VAT ID: DE235056961

Back to news